/
Oncology
Gastric Adenocarcinoma
35
Pipeline Programs↗
38
Active Trials↗
30
Companies Involved↗
Gastric Adenocarcinoma is a moderately active landscape with 35 programs across 30 companies. The most active players are AstraZeneca. 9 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical4
Phase 220
Phase 39
Approved
No programs
Analysis
Modality Breakdown
69%
Small molecule
22 of 32 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 32 classified programs, each share of the total. Modality classified for 97% of 35 pipeline programs.
Analysis
Trial Status
120
clinical trials
Completed40 · 33%
Unknown status31 · 26%
Recruiting17 · 14%
Not yet recruiting14 · 12%
Terminated8 · 7%
Active, not recruiting7 · 6%
Other3 · 3%
Clinical Trials
Trial Activity
120 trials
Perioperative Chemotherapy Combined With Serplulimab or Placebo for pMMR Locally Advanced Gastric Adenocarcinoma (FOCUS-05)
Recruiting·—·Phase 2·NCT05872685·314 enrolled
A Prospective Exploratory Study of SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Resectable Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT07464756·80 enrolled
Page 1 of 8
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)